Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Epizyme Inc (EPZM)

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,088,803
  • Shares Outstanding, K 91,037
  • Annual Sales, $ 21,700 K
  • Annual Income, $ -123,630 K
  • 60-Month Beta 2.46
  • Price/Sales 50.93
  • Price/Cash Flow N/A
  • Price/Book 3.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.53
  • Number of Estimates 7
  • High Estimate -0.36
  • Low Estimate -0.73
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +1.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.79 +1.44%
on 08/27/19
14.20 -15.77%
on 08/19/19
-0.78 (-6.12%)
since 08/13/19
3-Month
11.22 +6.60%
on 08/06/19
16.59 -27.91%
on 06/24/19
-0.04 (-0.33%)
since 06/13/19
52-Week
5.14 +132.68%
on 12/24/18
16.59 -27.91%
on 06/24/19
+1.76 (+17.25%)
since 09/13/18

Most Recent Stories

More News
Epizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EPZM : 11.96 (-1.48%)
Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced commercial executive, Grant Bogle, and research...

EPZM : 11.96 (-1.48%)
Epizyme to Participate in Upcoming September Conferences

Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate...

EPZM : 11.96 (-1.48%)
Epizyme Inc Set to Possibly Pullback After Yesterday's Rally of 4.36%

Epizyme Inc (NASDAQ:EPZM) traded in a range yesterday that spanned from a low of $12.82 to a high of $13.56. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $12.98...

EPZM : 11.96 (-1.48%)
Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat

Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.

CELG : 98.40 (-0.23%)
NVS : 86.99 (-2.79%)
RHHBY : 34.4900 (+1.71%)
EPZM : 11.96 (-1.48%)
Relatively Good Performance Detected in Shares of Epizyme Inc in the Biotechnology Industry (EPZM , AIMT , VCYT , NVTA , FLXN )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

VCYT : 25.74 (+2.43%)
AIMT : 24.67 (-3.10%)
EPZM : 11.96 (-1.48%)
Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates

Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.

BGNE : 134.19 (+0.83%)
ACOR : 3.86 (+0.26%)
EPZM : 11.96 (-1.48%)
ETON : 6.24 (+0.48%)
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 0.00% and 424.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

EPZM : 11.96 (-1.48%)
Epizyme: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Friday reported a loss of $48.5 million in its second quarter.

EPZM : 11.96 (-1.48%)
Epizyme Reports Business Progress and Second Quarter 2019 Results

--Industry Veteran Paolo Tombesi Appointed as Chief Financial Officer

EPZM : 11.96 (-1.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade EPZM with:

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 12.79
1st Resistance Point 12.37
Last Price 11.96
1st Support Level 11.75
2nd Support Level 11.55

See More

52-Week High 16.59
Fibonacci 61.8% 12.22
Last Price 11.96
Fibonacci 50% 10.86
Fibonacci 38.2% 9.51
52-Week Low 5.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar